TP53 and urinary bladder cancer: For basal molecular subtype of bladder cancer recurrence, PD-L1 expression profile of both high- and low-grade specimens was significantly low—21.0 ± 1.7% and 6.9 ± 1.0%, respectively (p = 0.001, intergroup comparison), whereas double-negative p53-mutant highly malignant relapsed tumors exhibited 40.8 ± 3.2% of positively-stained cells (p = 0.001, in comparison with the low-malignant subgroup, where only 16.8 ± 1.1% of tumor cells expressed PD-L1).